miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.

Bacci, Marina; Giannoni, Elisa; Fearns, Antony; Ribas, Ricardo; Gao, Qiong; Taddei, Maria Letizia; Pintus, Gianfranco; Dowsett, Mitch; Isacke, Clare M; Martin, Lesley-Ann; Chiarugi, Paola; Morandi, Andrea

Bacci, Marina; Giannoni, Elisa; Fearns, Antony; Ribas, Ricardo; Gao, Qiong; Taddei, Maria Letizia; Pintus, Gianfranco; Dowsett, Mitch; Isacke, Clare M; Martin, Lesley-Ann; Chiarugi, Paola; Morandi, Andrea.

Afiliação

Bacci M; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Giannoni E; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Fearns A; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Ribas R; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Gao Q; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Taddei ML; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Pintus G; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Dowsett M; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom. Academic Department of Biochemistry, The Royal Marsden Hospital, London, United Kingdom.
Isacke CM; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Martin LA; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Chiarugi P; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. Tuscany Tumor Institute (ITT) and Excellence Centre for Research, Transfer and High Education DenoTHE, Florence, Italy. andrea.morandi@unifi.it paola.chiarugi@unifi.it.
Morandi A; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. andrea.morandi@unifi.it paola.chiarugi@unifi.it.

Cancer Res ; 76(6): 1615-26, 2016 Mar 15.

Article em En | MEDLINE | ID: mdl-26795347

Assuntos

Inibidores da Aromatase/farmacologia; Neoplasias da Mama/genética; Estrogênios/genética; MicroRNAs/genética; Receptores de Estrogênio/genética; Anastrozol; Animais; Antineoplásicos/farmacologia; Neoplasias da Mama/tratamento farmacológico; Linhagem Celular Tumoral; Sobrevivência Celular/efeitos dos fármacos; Sobrevivência Celular/genética; Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos; Resistencia a Medicamentos Antineoplásicos/genética; Feminino; Glicólise/efeitos dos fármacos; Glicólise/genética; Hexoquinase/genética; Humanos; Letrozol; Células MCF-7; Camundongos; Camundongos Nus; Terapia Neoadjuvante/métodos; Nitrilas/farmacologia; Fosforilação/efeitos dos fármacos; Fosforilação/genética; Triazóis/farmacologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / MicroRNAs / Inibidores da Aromatase / Estrogênios Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google